Ads
related to: cancer, herceptin- Side Effect Management
Managing side effects
and planning ahead.
- Mechanism Of Action
Visit the site and learn
how NERLYNX works.
- Access And Support
Useful information for you
and your patients.
- Clinical Guidelines
Get familiar with guideline
recommendations for NERLYNX.
- Clinical Studies
Learn about NERLYNX efficacy
including safety information.
- Patient Support Program
Enroll your eligible patients in
Puma Patient Lynx™ support program.
- Side Effect Management
Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoIt will be historic when it is no longer the first prescribed agent in HER2+ mBC and Enhertu may...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
AOL· 5 days agoThe findings, presented in Chicago at the annual meeting of the American Society of Clinical Oncology, significantly broaden the range of breast cancer patients that could ...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 3 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 4 days agoARX788 is attempting to enter a crowded field, Enhertu (trastuzumab deruxtecan) is the standard of...
...Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer - ALX...
Benzinga· 5 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
FierceBiotech· 6 days agoAs zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks via Yahoo Finance· 2 days agoThe outlook for 2024 is ordinary as well. Competition from biosimilars for established cancer...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 3 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
Ads
related to: cancer, herceptin